[ad_1] First quarter 2023 Total Revenue of $26.1 million which includes TAVALISSE® net product sales of $22.3 million and REZLIDHIA® net product sales of $1.5 million Global expansion of TAVALISSE…
[ad_1] First quarter 2023 Total Revenue of $26.1 million which includes TAVALISSE® net product sales of $22.3 million and REZLIDHIA® net product sales of $1.5 million Global expansion of TAVALISSE…